A Comprehensive Multi-Omics AI Approach, Proven Drug Discovery Capabilities, and Deep Neuroscience Expertise
As CNS drug discovery grows more complex, so does the need for smarter, more integrated approaches to target identification and validation. In this poster, Sygnature Discovery outlines a comprehensive platform combining multi-omics data, AI-powered analysis, and deep neuroscience expertise to accelerate discovery for neurodegenerative and neuroinflammatory disorders. By combining proven drug discovery capabilities, a modular neuroscience platform, and deep therapeutic expertise, we accelerate the path from data to clinical candidates—tailored to client goals and underpinned by expert-driven decision-making.
Our Multi-Omics AI Approach
Diseases of the central nervous system often involve multifactorial pathways and subtle molecular drivers that single-layer data can miss. A multi-omics strategy—integrating genomics, transcriptomics, proteomics and phenotypic data—offers us a more holistic view, enabling precise prioritisation of disease-relevant targets.
Our approach enhances this by:
- Applying AI and network-based analytics to detect high-confidence, druggable targets
- Linking omics data with patient-derived iPSC models and functional phenotypic screening
- Aligning output with proven medicinal chemistry and biology workflows for seamless progression
Sygnature’s Neuroscience Capabilities & Drug Discovery Expertise
Underpinned by decades of neuroscience and drug discovery expertise, our integrated platform enables clients to:
- Rapidly identify and validate novel CNS targets
- Align target selection with therapeutic relevance and tractability to take your target through to hit identification.
- Translate early discovery insights into robust candidate nomination to enhance your candidate’s chance of success in the clinic.
Download the full poster to learn how Sygnature’s tailored, data-driven approach is transforming neuroscience drug discovery.
At Sygnature Discovery our neuroscience teams take a tailored, data driven approach to advance your CNS pipeline with confidence. Speak to the team today to learn more.